Pharma Adam Feuerstein Is ‘STING’ a new and promising cancer target? Don’t look at Merck’s study results for a definitive answer
Adam's Take Adam Feuerstein The investor euphoria for Incyte’s experimental cancer drug is hard to rationalize
Pharma Adam Feuerstein AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients
Biotech Arlene Weintraub A biotech firm, on the brink of ruin, resurrects itself via man — and microbe